The DOI matches its Crossref record; 882 of the 882 references it cites were found in a registry or an index.
Cold and hot tumors: from molecular mechanisms to targeted therapy
Open accessAbstract
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which has shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment in cancer therapy, only a minority of patients exhibit a positive response to it. In patients with solid tumors, those who respond well to ICB treatment typically demonstrate an active immune profile referred to as the “hot” (immune-inflamed) phenotype. On the other hand, non-responsive patients may exhibit a distinct “cold” (immune-desert) phenotype, differing from the features of “hot” tumors. Additionally, there is a more nuanced “excluded” immune phenotype, positioned between the “cold” and “hot” categories, known as the immune “excluded” type. Effective differentiation between “cold” and “hot” tumors, and understanding tumor intrinsic factors, immune characteristics, TME, and external factors are critical for predicting tumor response and treatment results. It is widely accepted that ICB therapy exerts a more profound effect on “hot” tumors, with limited efficacy against “cold” or “altered” tumors, necessitating combinations with other therapeutic modalities to enhance immune cell infiltration into tumor tissue and convert “cold” or “altered” tumors into “hot” ones. Therefore, aligning with the traits of “cold” and “hot” tumors, this review systematically delineates the respective immune characteristics, influencing factors, and extensively discusses varied treatment approaches and drug targets based on “cold” and “hot” tumors to assess clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 882
Carozza, J. A., Böhnert, V., Nguyen, K. C., Skariah, G., Shaw, K. E., Brown, J. A., Rafat, M., von Eyben, R., Graves, E. E., Glenn, J. S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0028-4 · Cited by 357
Hyaluronic Acid and Controlled Release: A Review
Bayer, I. S. (2020) · Molecules · doi:10.3390/molecules25112649 · Cited by 356
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Liu, J., Zhang, X., Chen, K., Cheng, Y., Liu, S., Xia, M., Chen, Y., Zhu, H., Li, Z., & Cao, X. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.021 · Cited by 351
BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells
Seo, H., González-Avalos, E., Zhang, W., Ramchandani, P., Yang, C., Lio, C.-W. J., Rao, A., & Hogan, P. G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00964-8 · Cited by 350
Polyamines in cancer: integrating organismal metabolism and antitumour immunity
Holbert, C. E., Cullen, M. T., Casero, R. A., & Stewart, T. M. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00473-2 · Cited by 350
Pacella, I., Procaccini, C., Focaccetti, C., Miacci, S., Timperi, E., Faicchia, D., Severa, M., Rizzo, F., Coccia, E. M., Bonacina, F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720113115 · Cited by 344
Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., Yuan, L., & Feng, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1435-2 · Cited by 343
CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis
Yang, P., Qin, H., Li, Y., Xiao, A., Zheng, E., Zeng, H., Su, C., Luo, X., Lu, Q., Liao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33349-y · Cited by 342
Xu, J., Kato, K., Raymond, E., Hubner, R. A., Shu, Y., Pan, Y., Park, S. R., Ping, L., Jiang, Y., Zhang, J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00108-0 · Cited by 338
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E., Wu, A., Xia, Y., Garzon-Muvdi, T., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466769 · Cited by 336
Song, M., He, J., Pan, Q., Yang, J., Zhao, J., Zhang, Y., Huang, Y., Tang, Y., Wang, Q., He, J., et al. (2021) · Hepatology · doi:10.1002/hep.31792 · Cited by 336
Villablanca, E. J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A., Sanvito, F., Ponzoni, M., Valentinis, B., Bregni, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2074 · Cited by 335
LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance
Cunha, L. D., Yang, M., Carter, R., Guy, C., Harris, L., Crawford, J. C., Quarato, G., Boada-Romero, E., Kalkavan, H., Johnson, M. D. L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.061 · Cited by 334
SLC19A1 is an importer of the immunotransmitter cGAMP.
Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C., & Li, L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.006 · Cited by 333
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Dane, E. L., Belessiotis-Richards, A., Backlund, C., Wang, J., Hidaka, K., Milling, L. E., Bhagchandani, S., Melo, M. B., Wu, S., Li, N., et al. (2022) · Nature Materials · doi:10.1038/s41563-022-01251-z · Cited by 333
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Substrate Rigidity Regulates Human T Cell Activation and Proliferation
O’Connor, R. S., Hao, X., Shen, K., Bashour, K., Akimova, T., Hancock, W. W., Kam, L. C., & Milone, M. C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102757 · Cited by 329
Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C., Tai, Y., Zhang, Q., & Chen, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.020 · Cited by 328
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 327
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., Munn, D., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
Gonugunta, V. K., Sakai, T., Pokatayev, V., Yang, K., Wu, J., Dobbs, N., & Yan, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.061 · Cited by 323
Finley, L. W. S. (2023) · Cell · doi:10.1016/j.cell.2023.01.038 · Cited by 322
Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways
Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Chuan Goh, K., Williams, B. R. G., & Stark, G. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.2.263 · Cited by 319
Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318
Emerging Opportunities and Challenges in Cancer Immunotherapy
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 317
Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M., Penkov, K., Laktionov, K., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 316
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 315
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
Han, S., Bao, X., Zou, Y., Wang, L., Li, Y., Yang, L., Liao, A., Zhang, X., Jiang, X., Liang, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2697 · Cited by 310
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
Managing the TME to improve the efficacy of cancer therapy
Bilotta, M. T., Antignani, A., & Fitzgerald, D. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954992 · Cited by 309
Dietary palmitic acid promotes a prometastatic memory via Schwann cells
Pascual, G., Domínguez, D., Elosúa-Bayes, M., Beckedorff, F., Laudanna, C., Bigas, C., Douillet, D., Greco, C., Symeonidi, A., Hernández, I., et al. (2021) · Nature · doi:10.1038/s41586-021-04075-0 · Cited by 308
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307
Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L. P., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 306
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.001 · Cited by 306
Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment
Poznanski, S. M., Singh, K., Ritchie, T. M., Aguiar, J. A., Fan, I. Y., Portillo, A. L., Rojas, E. A., Vahedi, F., El-Sayes, A., Xing, S., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.023 · Cited by 306
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A., Komar, C., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben-Josef, E., & Beatty, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 305
Miska, J., Lee-Chang, C., Rashidi, A., Muroski, M. E., Chang, A. L., Lopez-Rosas, A., Zhang, P., Panek, W. K., Cordero, A., Han, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.029 · Cited by 304
Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 302
Xie, L., Li, J., Wang, G., Sang, W., Xu, M., Li, W., Yan, J., Li, B., Zhang, Z., Zhao, Q., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09753 · Cited by 301
Self-citationSlow TCA flux and ATP production in primary solid tumours but not metastases
Bartman, C. R., Weilandt, D. R., Shen, Y., Lee, W. D., Han, Y., TeSlaa, T., Jankowski, C. S. R., Samarah, L., Park, N. R., da Silva-Diz, V., et al. (2023) · Nature · doi:10.1038/s41586-022-05661-6 · Cited by 299
Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer
Unterleuthner, D., Neuhold, P., Schwarz, K., Janker, L., Neuditschko, B., Nivarthi, H., Crncec, I., Kramer, N., Unger, C., Hengstschläger, M., et al. (2020) · Angiogenesis · doi:10.1007/s10456-019-09688-8 · Cited by 299
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
West, E. E., Jin, H.-T., Rasheed, A.-U., Penaloza-MacMaster, P., Ha, S.-J., Tan, W. G., Youngblood, B., Freeman, G. J., Smith, K. A., & Ahmed, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67008 · Cited by 298
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity
Schadt, L., Sparano, C., Schweiger, N. A., Silina, K., Cecconi, V., Lucchiari, G., Yagita, H., Guggisberg, E., Saba, S., Nascakova, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.065 · Cited by 298
Maller, O., Drain, A. P., Barrett, A. S., Borgquist, S., Ruffell, B., Zakharevich, I., Pham, T. T., Gruosso, T., Kuasne, H., Lakins, J. N., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-00849-5 · Cited by 298
Chang, C., Liao, J. C., & Kuo, L. (2001) · PubMed · Cited by 294
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30262-0 · Cited by 293
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Gok Yavuz, B., Gunaydin, G., Gedik, M. E., Kosemehmetoglu, K., Karakoc, D., Ozgur, F., & Guc, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-39553-z · Cited by 292
Cohen, N., Shani, O., Raz, Y., Sharon, Y., Hoffman, D., Abramovitz, L., & Erez, N. (2017) · Oncogene · doi:10.1038/onc.2017.65 · Cited by 292
Zhou, C., Chen, X., Planells-Cases, R., Chu, J., Wang, L., Cao, L., Li, Z., López-Cayuqueo, K. I., Xie, Y., Ye, S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.016 · Cited by 291
Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity
Nava Lauson, C. B., Tiberti, S., Corsetto, P. A., Conte, F., Tyagi, P., Machwirth, M., Ebert, S., Loffreda, A., Scheller, L., Sheta, D., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.02.013 · Cited by 291
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W.-H., Qiu, Y., Stamatatos, O., Janowitz, T., & Lukey, M. J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 287
Immune mechanisms of toxicity from checkpoint inhibitors
Wang, S. J., Dougan, S. K., & Dougan, M. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.04.002 · Cited by 285
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 279
Grabosch, S., Bulatovic, M., Zeng, F., Ma, T., Zhang, L., Ross, M., Brozick, J., Fang, Y., Tseng, G., Kim, E., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0581-9 · Cited by 278
Konno, H., Yamauchi, S., Berglund, A., Putney, R. M., Mulé, J. J., & Barber, G. N. (2018) · Oncogene · doi:10.1038/s41388-017-0120-0 · Cited by 274
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H.-R., Pyle, K. J., Hipkiss, E., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T., Vatan, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 271
Rapp, M., Wintergerst, M. W. M., Kunz, W. G., Vetter, V. K., Knott, M. M. L., Lisowski, D., Haubner, S., Moder, S., Thaler, R., Eiber, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20170277 · Cited by 271
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 270
de Mingo Pulido, Á., Hänggi, K., Celias, D. P., Gardner, A., Li, J., Batista-Bittencourt, B., Mohamed, E., Trillo-Tinoco, J., Osunmakinde, O., Peña, R., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.019 · Cited by 270
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., et al. (2017) · Nature · doi:10.1038/nature22311 · Cited by 269
Kawazoe, A., Fukuoka, S., Nakamura, Y., Kuboki, Y., Wakabayashi, M., Nomura, S., Mikamoto, Y., Shima, H., Fujishiro, N., Higuchi, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30271-0 · Cited by 269
Cheng, J.-T., Deng, Y.-N., Yi, H.-M., Wang, G.-Y., Fu, B.-S., Chen, W.-J., Liu, W., Tai, Y., Peng, Y.-W., & Zhang, Q. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.7 · Cited by 267
Wang, Y., Lin, Y.-X., Qiao, S.-L., An, H.-W., Ma, Y., Qiao, Z.-Y., Rajapaksha, R. P. Y. J., & Wang, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 266
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M., Mauceri, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 265
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.028 · Cited by 264
Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.074 · Cited by 264
Arwert, E. N., Harney, A. S., Entenberg, D., Wang, Y., Sahai, E., Pollard, J. W., & Condeelis, J. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.007 · Cited by 263
Yu, B., Choi, B., Li, W., & Kim, D.-H. (2020) · Nature Communications · doi:10.1038/s41467-020-17380-5 · Cited by 262
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Biasci, D., Smoragiewicz, M., Connell, C. M., Wang, Z., Gao, Y., Thaventhiran, J. E. D., Basu, B., Magiera, L., Johnson, T. I., Bax, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013644117 · Cited by 262
Conche, C., Finkelmeier, F., Pešić, M., Nicolas, A. M., Böttger, T. W., Kennel, K. B., Denk, D., Ceteci, F., Mohs, K., Engel, E., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327909 · Cited by 262
The molecular basis of tight nuclear tethering and inactivation of cGAS
Zhao, B., Xu, P., Rowlett, C. M., Jing, T., Shinde, O., Lei, Y., West, A. P., Liu, W. R., & Li, P. (2020) · Nature · doi:10.1038/s41586-020-2749-z · Cited by 261
Tissue-resident macrophages are locally programmed for silent clearance of apoptotic cells
Roberts, A. W., Lee, B. L., Deguine, J., John, S., Shlomchik, M. J., & Barton, G. M. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.006 · Cited by 261
Luo, X., Gong, H.-B., Gao, H.-Y., Wu, Y.-P., Sun, W.-Y., Li, Z.-Q., Wang, G., Liu, B., Liang, L., Kurihara, H., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00719-2 · Cited by 261
Takahashi, H., Sakakura, K., Kudo, T., Toyoda, M., Kaira, K., Oyama, T., & Chikamatsu, K. (2017) · Oncotarget · doi:10.18632/oncotarget.14374 · Cited by 259
Mahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258
Self-citationKumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
Li, X., Yong, T., Wei, Z., Bie, N., Zhang, X., Zhan, G., Li, J., Qin, J., Yu, J., Zhang, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30306-7 · Cited by 257
Self-citationTurning up the heat on non-immunoreactive tumours: opportunities for clinical development
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 256
Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255
Maldonado, L., Teague, J. E., Morrow, M. P., Jotova, I., Wu, T. C., Wang, C., Desmarais, C., Boyer, J. D., Tycko, B., Robins, H. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007323 · Cited by 255
Du, S.-S., Chen, G.-W., Yang, P., Chen, Y.-X., Hu, Y., Zhao, Q.-Q., Zhang, Y., Liu, R., Zheng, D.-X., Zhou, J., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.162 · Cited by 252
Ding, G.-Y., Ma, J.-Q., Yun, J.-P., Chen, X., Ling, Y., Zhang, S., Shi, J.-Y., Chang, Y.-Q., Ji, Y., Wang, X.-Y., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.030 · Cited by 251
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sanchez, N., Guria, A., Minker, M., Li, G., Fisher, V., Sokol, E. S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 248
Hong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
Liu, J., Zhang, N., Li, Q., Zhang, W., Ke, F., Leng, Q., Wang, H., Chen, J., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019495 · Cited by 245
Assessing the interactions between radiotherapy and antitumour immunity
Grassberger, C., Ellsworth, S. G., Wilks, M. Q., Keane, F. K., & Loeffler, J. S. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0238-9 · Cited by 244
Therapeutic targeting of regulatory T cells in cancer
Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 244
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 241
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
Bauer, C. A., Kim, E. Y., Marangoni, F., Carrizosa, E., Claudio, N. M., & Mempel, T. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66375 · Cited by 238
Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237
Cancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 236
Wang, D., Yang, L., Yu, W., Wu, Q., Lian, J., Li, F., Liu, S., Li, A., He, Z., Liu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0701-2 · Cited by 234
Liu, T., Zhu, C., Chen, X., Guan, G., Zou, C., Shen, S., Wu, J., Wang, Y., Lin, Z., Chen, L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac033 · Cited by 233
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231
Zhao, Y., Liu, Z., Liu, G., Zhang, Y., Liu, S., Gan, D., Chang, W., Peng, X., Sung, E. S., Gilbert, K., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.09.004 · Cited by 228
Mesenchymal stem cells promote growth and angiogenesis of tumors in mice
Huang, W.-H., Chang, M.-C., Tsai, K.-S., Hung, M.-C., Chen, H.-L., & Hung, S.-C. (2013) · Oncogene · doi:10.1038/onc.2012.458 · Cited by 227
Rational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 227
Chaturvedi, P., Gilkes, D. M., Takano, N., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406655111 · Cited by 226
Lee, S. E., Kim, S. Y., Jeong, B. C., Kim, Y. R., Bae, S. J., Ahn, O. S., Lee, J.-J., Song, H.-C., Kim, J. M., Choy, H. E., et al. (2006) · Infection and Immunity · doi:10.1128/iai.74.1.694-702.2006 · Cited by 226
Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L., Chen, J., Huang, X. F., & Chen, S.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 226
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Su, S., Liao, J., Liu, J., Huang, D., He, C., Chen, F., Yang, L., Wu, W., Chen, J., Lin, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.34 · Cited by 225
Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W. W., Lizée, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0712 · Cited by 222
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221
Tietscher, S., Wagner, J., Anzeneder, T., Langwieder, C., Rees, M., Sobottka, B., de Souza, N., & Bodenmiller, B. (2023) · Nature Communications · doi:10.1038/s41467-022-35238-w · Cited by 221
CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome
Huang, Y., Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Hunborg, P., Varvares, M. A., Hoft, D. F., Hsueh, E. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3958 · Cited by 220
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Yoshimi, A., Lin, K.-T., Wiseman, D. H., Rahman, M. A., Pastore, A., Wang, B., Lee, S. C.-W., Micol, J.-B., Zhang, X. J., de Botton, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1618-0 · Cited by 220
Hickman, H. D., Reynoso, G. V., Ngudiankama, B. F., Cush, S. S., Gibbs, J., Bennink, J. R., & Yewdell, J. W. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.009 · Cited by 217
Zhang, A., Qian, Y., Ye, Z., Chen, H., Xie, H., Zhou, L., Shen, Y., & Zheng, S. (2017) · Cancer Medicine · doi:10.1002/cam4.993 · Cited by 216
Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases
Guo, C.-J., Chang, F.-Y., Wyche, T. P., Backus, K. M., Acker, T. M., Funabashi, M., Taketani, M., Donia, M. S., Nayfach, S., Pollard, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.021 · Cited by 215
Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0297 · Cited by 213
Granier, C., Dariane, C., Combe, P., Verkarre, V., Urien, S., Badoual, C., Roussel, H., Mandavit, M., Ravel, P., Sibony, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0274 · Cited by 213
Kim, G., McKee, A. E., Ning, Y.-M., Hazarika, M., Theoret, M., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 212
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells
Klarquist, J., Hennies, C. M., Lehn, M. A., Reboulet, R. A., Feau, S., & Janssen, E. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401869 · Cited by 211
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Di Pilato, M., Kim, E. Y., Cadilha, B. L., Prüßmann, J. N., Nasrallah, M. N., Seruggia, D., Usmani, S. M., Misale, S., Zappulli, V., Carrizosa, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1215-2 · Cited by 210
Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03205 · Cited by 210
Di Conza, G., Tsai, C.-H., Gallart-Ayala, H., Yu, Y.-R., Franco, F., Zaffalon, L., Xie, X., Li, X., Xiao, Z., Raines, L. N., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01047-4 · Cited by 206
Liu, Y., Niu, R., Deng, R., Song, S., Wang, Y., & Zhang, H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13689 · Cited by 206
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
Tumor-induced stromal reprogramming drives lymph node transformation
Riedel, A., Shorthouse, D., Haas, L., Hall, B. A., & Shields, J. (2016) · Nature Immunology · doi:10.1038/ni.3492 · Cited by 204
ER-directed TREX1 limits cGAS activation at micronuclei
Mohr, L., Toufektchan, E., von Morgen, P., Chu, K., Kapoor, A., & Maciejowski, J. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.037 · Cited by 204
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S., Pedde, A.-M., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 203
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., Yan, L., Targan, S., Solomon, J., Nichol, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 202
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion
Gunaydin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 202
Guan, B., Tong, J., Hao, H., Yang, Z., Chen, K., Xu, H., & Wang, A. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.011 · Cited by 202
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Barsoum, I. B., Koti, M., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2598 · Cited by 201
Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy
Wang, G., Yu, Y., Wang, Y., Wang, J., Guan, R., Sun, Y., Shi, F., Gao, J., & Fu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28436 · Cited by 199
Muri, J., Thut, H., Bornkamm, G. W., & Kopf, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.070 · Cited by 198
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
CAFs and TAMs: maestros of the tumour microenvironment
Komohara, Y., & Takeya, M. (2017) · The Journal of Pathology · doi:10.1002/path.4824 · Cited by 197
Song, W., Tiruthani, K., Wang, Y., Shen, L., Hu, M., Dorosheva, O., Qiu, K., Kinghorn, K. A., Liu, R., & Huang, L. (2018) · Advanced Materials · doi:10.1002/adma.201805007 · Cited by 194
Cadamuro, M., Brivio, S., Mertens, J., Vismara, M., Moncsek, A., Milani, C., Fingas, C., Cristina Malerba, M., Nardo, G., Dall'Olmo, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.004 · Cited by 193
Gorchs, L., Fernández Moro, C., Bankhead, P., Kern, K. P., Sadeak, I., Meng, Q., Rangelova, E., & Kaipe, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00847 · Cited by 193
Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0384 · Cited by 191
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Huseni, M. A., Wang, L., Klementowicz, J. E., Yuen, K., Breart, B., Orr, C., Liu, L.-F., Li, Y., Gupta, V., Li, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100878 · Cited by 188
Dynamic Mast Cell–Stromal Cell Interactions Promote Growth of Pancreatic Cancer
Ma, Y., Hwang, R. F., Logsdon, C. D., & Ullrich, S. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4479 · Cited by 186
Thomas, A., Vilimas, R., Trindade, C., Erwin-Cohen, R., Roper, N., Xi, L., Krishnasamy, V., Levy, E., Mammen, A., Nichols, S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.026 · Cited by 185
CAR T‐cell therapy: Full speed ahead
Sermer, D., & Brentjens, R. (2019) · Hematological Oncology · doi:10.1002/hon.2591 · Cited by 183
Cancer Immunotherapy Based on Killing of Salmonella -Infected Tumor Cells
Avogadri, F., Martinoli, C., Petrovska, L., Chiodoni, C., Transidico, P., Bronte, V., Longhi, R., Colombo, M. P., Dougan, G., & Rescigno, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3002 · Cited by 181
Li, C., Guo, H., Zhai, P., Yan, M., Liu, C., Wang, X., Shi, C., Li, J., Tong, T., Zhang, Z., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1448 · Cited by 181
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Li, K., Qu, S., Chen, X., Wu, Q., & Shi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020404 · Cited by 180
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 180
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 180
RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma
Lam, A. R., Le Bert, N., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179
Cunningham, T. J., Tabacchi, M., Eliane, J.-P., Tuchayi, S. M., Manivasagam, S., Mirzaalian, H., Turkoz, A., Kopan, R., Schaffer, A., Saavedra, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89820 · Cited by 178
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role
Gago da Graça, C., van Baarsen, L. G. M., & Mebius, R. E. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000873 · Cited by 178
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 178
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines
Demento, S. L., Siefert, A. L., Bandyopadhyay, A., Sharp, F. A., & Fahmy, T. M. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.02.004 · Cited by 176
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 176
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 175
Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell Activation
Pacheco, R., Oliva, H., Martinez-Navío, J. M., Climent, N., Ciruela, F., Gatell, J. M., Gallart, T., Mallol, J., Lluis, C., & Franco, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6695 · Cited by 174
Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy
Jia, J., Zhang, Y., Xin, Y., Jiang, C., Yan, B., & Zhai, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00404 · Cited by 174
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
De Clercq, E. (2019) · Antiviral Chemistry and Chemotherapy · doi:10.1177/2040206619829382 · Cited by 174
Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer
Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S., Wang, R., Rosario, A., Avalos, C., Schmolze, D., Yim, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174
TGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 174
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Tsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 172
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D'Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 172
Arensman, M. D., Yang, X. S., Leahy, D. M., Toral-Barza, L., Mileski, M., Rosfjord, E. C., Wang, F., Deng, S., Myers, J. S., Abraham, R. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814932116 · Cited by 171
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Guan, X., Hu, R., Choi, Y., Srivats, S., Nabet, B. Y., Silva, J., McGinnis, L. M., Hendricks, R., Nutsch, K., Banta, K. L., et al. (2024) · Nature · doi:10.1038/s41586-024-07121-9 · Cited by 171
Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer
He, W., Li, Q., & Li, X. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188837 · Cited by 169
Hua, Y., Vella, G., Rambow, F., Allen, E., Antoranz Martinez, A., Duhamel, M., Takeda, A., Jalkanen, S., Junius, S., Smeets, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.002 · Cited by 169
Wang, S., Wu, Q., Chen, T., Su, R., Pan, C., Qian, J., Huang, H., Yin, S., Xie, H., Zhou, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.011 · Cited by 168
Li, G., Choi, J. E., Kryczek, I., Sun, Y., Liao, P., Li, S., Wei, S., Grove, S., Vatan, L., Nelson, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.008 · Cited by 168
Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167
Chang, W., Altman, M. D., Lesburg, C. A., Perera, S. A., Piesvaux, J., Schroeder, G. K., Wyss, D. F., Čemerski, S., Chen, Y., DiNunzio, E., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02197 · Cited by 167
Kinkead, H. L., Hopkins, A., Lutz, E., Wu, A. A., Yarchoan, M., Cruz, K., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 166
Ji, D., Song, C., Li, Y., Xia, J., Wu, Y., Jia, J., Cui, X., Yu, S., & Gu, J. F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000826 · Cited by 166
GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment
Missiaen, R., Anderson, N. M., Kim, L. C., Nance, B., Burrows, M., Skuli, N., Carens, M., Riscal, R., Steensels, A., Li, F., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.010 · Cited by 166
Beltra, J., Abdel-Hakeem, M. S., Manne, S., Zhang, Z., Huang, H., Kurachi, M., Su, L., Picton, L. K., Ngiow, S. F., Muroyama, Y., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.005 · Cited by 166
Intracellular Pathogen Detection by RIG-I-Like Receptors
Dixit, E., & Kagan, J. C. (2013) · Advances in Immunology · doi:10.1016/b978-0-12-410524-9.00004-9 · Cited by 165
Duperret, E. K., Trautz, A., Ammons, D. T., Perales‐Puchalt, A., Wise, M. C., Yan, J., Reed, C., & Weiner, D. B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2033 · Cited by 165
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Dendritic cells in the tumor microenvironment: prognostic and theranostic impact
Verneau, J., Sautés-Fridman, C., & Sun, C.-M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101410 · Cited by 165
Zhu, G., Su, H., Johnson, C. H., Khan, S. A., Kluger, H. M., & Lu, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.053 · Cited by 165
Koerner, J., Horvath, D., Herrmann, V. L., MacKerracher, A., Gander, B., Yagita, H., Rohayem, J., & Groettrup, M. (2021) · Nature Communications · doi:10.1038/s41467-021-23244-3 · Cited by 164
Derks, S., de Klerk, L. K., Xu, X., Fleitas, T., Liu, K. X., Liu, Y., Dietlein, F., Margolis, C., Chiaravalli, A. M., Da Silva, A. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.011 · Cited by 163
Self-citationUtilizing chemokines in cancer immunotherapy
Märkl, F., Huynh, D., Endres, S., & Kobold, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.001 · Cited by 163
Liang, D., Huang, X., Guan-Jun, D., Hu, E., Sheng, C., Wang, T., Hu, Q., Ni, Y., & Ya-yi, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.011 · Cited by 161
Zhang, P., Chiu, Y.-C., Tostanoski, L. H., & Jewell, C. M. (2015) · ACS Nano · doi:10.1021/acsnano.5b02153 · Cited by 161
Wang, Y., Tiruthani, K., Li, S., Hu, M., Zhong, G., Tang, Y., Roy, S., Zhang, L., Tan, J. H., Liao, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007603 · Cited by 161
Cited by
Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy
Kim, H. C., Kim, H.-J., La, J., Park, W. H., Park, S. H., Kang, B. H., Kim, Y., & Lee, H. K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115825 · Cited by 23
Metadata
- Authors
- Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-10-18
- Volume
- 9
- Issue
- 1
- Pages
- 274-274
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4403506731
- Cited by
- 682
- References
- 882
- FWCI
- 104.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.